Human Acellular Vessel not checked

Humacyte, Inc.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.”In the company’s words, NCT03183245 on ClinicalTrials.gov
Tested for
Renal Failure (2 trials), End Stage Renal Disease (2 trials), Hemodialysis (2 trials), Vascular Access (2 trials), Peripheral Artery Disease
Main trialPhase 3
“The main purpose of this study is to compare the Human Acellular Vessel (HAV) with ePTFE grafts when used for hemodialysis access.”In the company’s words, NCT02644941 on ClinicalTrials.gov

Other drugs for Renal Failure

All 108 drugs for Renal Failure

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials3

TrialPhaseCompletesWhat it tests
Phase 3Completed May 2019 Comparison of the Human Acellular Vessel (HAV) With ePTFE Grafts as Conduits for Hemodialysis
Phase 3Completed 22 Apr 2024 Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
Phase 2Completed Dec 2020 Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Human Acellular Vessel

Following is part of Solo: you see every change to Human Acellular Vessel the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in